View in EDS

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.

Saved in:
Bibliographic Details
Title: Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Authors: Kater AP; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands. Electronic address: a.p.kater@amsterdamumc.nl., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands., Dubois J; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands., Kersting S; Department of Hematology, Haga Hospital, Den Haag, Netherlands., Enggaard L; Department of Hematology, Herlev Hospital, Copenhagen, Denmark., Veldhuis GJ; Department of Hematology, St Antonius Hospital, Sneek, Netherlands., Mous R; Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands., Mellink CHM; Department of Human Genetics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands., van der Kevie-Kersemaekers AF; Department of Human Genetics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands., Dobber JA; Laboratory of Special Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands., Poulsen CB; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Frederiksen H; Department of Hematology, Odense University Hospital, Odense, Denmark., Janssens A; Department of Hematology, UZ Leuven, Leuven, Belgium., Schjødt I; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Dompeling EC; Department of Hematology, Isala Ziekenhuis, Zwolle, Netherlands., Ranti J; Department of Hematology, Turku University Central Hospital, Turku, Finland., Brieghel C; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Mattsson M; Department of Hematology, Uppsala University Hospital, Uppsala, Sweden., Bellido M; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands., Tran HTT; Department of Hematology, Akershus University Hospital, Lørenskog, Norway., Nasserinejad K; HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands., Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: carsten.utoft.niemann@regionh.dk.
Source: The Lancet. Oncology [Lancet Oncol] 2022 Jun; Vol. 23 (6), pp. 818-828.
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Lancet Pub. Group Country of Publication: England NLM ID: 100957246 Publication Model: Print Cited Medium: Internet ISSN: 1474-5488 (Electronic) Linking ISSN: 14702045 NLM ISO Abbreviation: Lancet Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35654052
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Kater+AP%22">Kater AP</searchLink>; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands. Electronic address: a.p.kater@amsterdamumc.nl.<br /><searchLink fieldCode="AU" term="%22Levin+MD%22">Levin MD</searchLink>; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Dubois+J%22">Dubois J</searchLink>; Department of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Kersting+S%22">Kersting S</searchLink>; Department of Hematology, Haga Hospital, Den Haag, Netherlands.<br /><searchLink fieldCode="AU" term="%22Enggaard+L%22">Enggaard L</searchLink>; Department of Hematology, Herlev Hospital, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Veldhuis+GJ%22">Veldhuis GJ</searchLink>; Department of Hematology, St Antonius Hospital, Sneek, Netherlands.<br /><searchLink fieldCode="AU" term="%22Mous+R%22">Mous R</searchLink>; Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands.<br /><searchLink fieldCode="AU" term="%22Mellink+CHM%22">Mellink CHM</searchLink>; Department of Human Genetics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Kevie-Kersemaekers+AF%22">van der Kevie-Kersemaekers AF</searchLink>; Department of Human Genetics, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Dobber+JA%22">Dobber JA</searchLink>; Laboratory of Special Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Poulsen+CB%22">Poulsen CB</searchLink>; Department of Hematology, Zealand University Hospital, Roskilde, Denmark.<br /><searchLink fieldCode="AU" term="%22Frederiksen+H%22">Frederiksen H</searchLink>; Department of Hematology, Odense University Hospital, Odense, Denmark.<br /><searchLink fieldCode="AU" term="%22Janssens+A%22">Janssens A</searchLink>; Department of Hematology, UZ Leuven, Leuven, Belgium.<br /><searchLink fieldCode="AU" term="%22Schjødt+I%22">Schjødt I</searchLink>; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Dompeling+EC%22">Dompeling EC</searchLink>; Department of Hematology, Isala Ziekenhuis, Zwolle, Netherlands.<br /><searchLink fieldCode="AU" term="%22Ranti+J%22">Ranti J</searchLink>; Department of Hematology, Turku University Central Hospital, Turku, Finland.<br /><searchLink fieldCode="AU" term="%22Brieghel+C%22">Brieghel C</searchLink>; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.<br /><searchLink fieldCode="AU" term="%22Mattsson+M%22">Mattsson M</searchLink>; Department of Hematology, Uppsala University Hospital, Uppsala, Sweden.<br /><searchLink fieldCode="AU" term="%22Bellido+M%22">Bellido M</searchLink>; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.<br /><searchLink fieldCode="AU" term="%22Tran+HTT%22">Tran HTT</searchLink>; Department of Hematology, Akershus University Hospital, Lørenskog, Norway.<br /><searchLink fieldCode="AU" term="%22Nasserinejad+K%22">Nasserinejad K</searchLink>; HOVON Data Center, Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Niemann+CU%22">Niemann CU</searchLink>; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: carsten.utoft.niemann@regionh.dk.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100957246%22">The Lancet. Oncology</searchLink> [Lancet Oncol] 2022 Jun; Vol. 23 (6), pp. 818-828.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Lancet+Pub%2E+Group%22">Lancet Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100957246 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1474-5488 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214702045%22">14702045 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35654052
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S1470-2045(22)00220-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 818
    Titles:
      – TitleFull: Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Kater AP
      – PersonEntity:
          Name:
            NameFull: Levin MD
      – PersonEntity:
          Name:
            NameFull: Dubois J
      – PersonEntity:
          Name:
            NameFull: Kersting S
      – PersonEntity:
          Name:
            NameFull: Enggaard L
      – PersonEntity:
          Name:
            NameFull: Veldhuis GJ
      – PersonEntity:
          Name:
            NameFull: Mous R
      – PersonEntity:
          Name:
            NameFull: Mellink CHM
      – PersonEntity:
          Name:
            NameFull: van der Kevie-Kersemaekers AF
      – PersonEntity:
          Name:
            NameFull: Dobber JA
      – PersonEntity:
          Name:
            NameFull: Poulsen CB
      – PersonEntity:
          Name:
            NameFull: Frederiksen H
      – PersonEntity:
          Name:
            NameFull: Janssens A
      – PersonEntity:
          Name:
            NameFull: Schjødt I
      – PersonEntity:
          Name:
            NameFull: Dompeling EC
      – PersonEntity:
          Name:
            NameFull: Ranti J
      – PersonEntity:
          Name:
            NameFull: Brieghel C
      – PersonEntity:
          Name:
            NameFull: Mattsson M
      – PersonEntity:
          Name:
            NameFull: Bellido M
      – PersonEntity:
          Name:
            NameFull: Tran HTT
      – PersonEntity:
          Name:
            NameFull: Nasserinejad K
      – PersonEntity:
          Name:
            NameFull: Niemann CU
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2022 Jun
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1474-5488
          Numbering:
            – Type: volume
              Value: 23
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: The Lancet. Oncology
              Type: main
ResultId 1